Varicella Zoster (HHV-3) Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections – Drugs In Development, 2023’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
- The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adjuvance Technologies IncAmytrx Therapeutics Inc
Barinthus Biotherapeutics Plc
Beijing Green Bamboo Biotechnology Co Ltd
Beijing Health Guard Biotechnology Inc
Beijing Institute of Biological Products
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Minhai Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
Biological E Ltd
BioNTech SE
BMI Korea Co Ltd
BravoVax Co Ltd
CanSino Biologics Inc
CHA Vaccine Institute Co Ltd
Changchun Institute of Biological Products Co Ltd
China National Pharmaceutical Group Corp
Chongqing Zhifei Biological Products Co Ltd
Curevo Inc
DongKoo Bio & Pharma Co Ltd
Dynavax Technologies Corp
EyeGene Inc
Fort Lewis College
Genrix (Shanghai) Biopharmaceutical Co Ltd
GreenLight Biosciences Holdings PBC
GSK plc
HDT Bio Corp
Immorna Hangzhou Biotechnology Co Ltd
Indian Immunologicals Ltd
Jiangsu Recbio Technology Co Ltd
Lee's Pharmaceutical Holdings Ltd
Liaoning Chengda Biological Co Ltd
MAXVAX Biotechnology Co Ltd
Mayly Life Sciences
Moderna Inc
NAL Pharmaceuticals Ltd
Nanjing Yuandasai Weixin Biomedical Co Ltd
NanoViricides Inc
Pfizer Inc
RNAimmune Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Institute of Biological Products Co Ltd
Shanghai Yidao Biological Technology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
Shulov Innovative Science Ltd
SK Bioscience Ltd
Stemirna Therapeutics Ltd
Suzhou Abogen Biosciences Co Ltd
TTY Biopharm Co Ltd
Vapogenix Inc
Varnotech
Vernagen Inc
ViroStatics SRL
Walvax Biotechnology Co Ltd
Wintermute Biomedical LLC
XBiotech Inc
Yisheng Biopharma Co Ltd
Zhongyianke Biotech Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd